Back to Cell Types

HDLM-2Homo sapiens (Human)Cancer cell line

Also known as: HDLM2, HD-LM-2

🤖 AI SummaryBased on 11 publications

Quick Overview

HDLM-2 is a Hodgkin lymphoma cell line used in cancer research.

Detailed Summary

HDLM-2 is a cell line derived from Hodgkin lymphoma, specifically from the pleural effusion of a 74-year-old male patient. It is characterized by its ability to undergo differentiation when exposed to 12-O-tetradecanoylphorbol 13-acetate (TPA), showing morphological changes indicative of myeloid lineage differentiation. The cell line exhibits unique isoenzyme profiles and lacks typical T- or B-cell markers, suggesting a distinct lineage. HDLM-2 has been used in studies investigating the molecular mechanisms of Hodgkin lymphoma, including the role of p53 mutations and the impact of TPA on cell differentiation and proliferation.

Research Applications

Cancer researchMolecular mechanisms of Hodgkin lymphomaDifferentiation studiesIsoenzyme profiling

Key Characteristics

TPA-induced differentiationMyeloid lineage differentiation markersp53 mutationsUnique isoenzyme profiles

Generated on 6/14/2025

Basic Information

Database ID	CVCL_0009
Species	Homo sapiens (Human)
Tissue Source	Pleural effusion[UBERON:UBERON_0000175]

Donor Information

Age	74
Age Category	Adult
Sex	Male

Disease Information

Disease	Hodgkin lymphoma
Lineage	Lymphoid
Subtype	Hodgkin Lymphoma
OncoTree Code	HL

DepMap Information

Source Type	DSMZ
Source ID	ACH-000267_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationUnexplicit	TP53	Fusion with an Alu-element at the Ex7-Ex8 junction	Unspecified	-	from parent cell line HDLM-2
MutationSimple	TNFAIP3	p.Met174fs (c.520_548dup) (dup 586-614)	Heterozygous	-	PubMed=19380639
Gene deletion	TNFAIP3	-	Heterozygous	-	PubMed=19380639

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

11,12

D13S317

11,12

D16S539

12

D18S51

14

D19S433

12,15

D21S11

29

D2S1338

17

D3S1358

14,15

D5S818

11

D7S820

8,10

D8S1179

13,14

FGA

21,23

Penta D

13,14

Penta E

12

TH01

6,7

TPOX

8

vWA

19

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";

Drexler H.G., Pommerenke C., Eberth S., Nagel S.

Biol. Chem. 399:511-523(2018).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

A mass spectrometric-derived cell surface protein atlas.";

Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.

PLoS ONE 10:E0121314-E0121314(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Kutok J.L., Shipp M.A.

Blood 116:3268-3277(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.

Stanelle J., Siebert R., Kuppers R.

J. Exp. Med. 206:981-989(2009).

Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma.

Sturzenhofecker B., Kube D.

Leuk. Lymphoma 47:1932-1940(2006).

Molecular cytogenetic characterization of four commonly used cell lines derived from Hodgkin lymphoma.

Lagercrantz S., Enblad G.

Cancer Genet. Cytogenet. 141:43-48(2003).

Telomere analysis by fluorescence in situ hybridization and flow cytometry.

Roos G.

Nucleic Acids Res. 26:3651-3656(1998).

The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.

Quentmeier H., Drexler H.G.

Leukemia 10:142-149(1996).

Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles.

Drexler H.G., Gaedicke G., Lok M.-S., Diehl V., Minowada J.

Leuk. Res. 10:487-500(1986).

Biology of Hodgkin cell lines.";

Tesch H., Fonatsch C., Stein H., Diehl V.

Recent Results Cancer Res. 117:53-61(1989).

Characterization of Hodgkin's disease derived cell line HDLM-2.";

Lok M.-S., Minowada J.

Recent Results Cancer Res. 117:75-82(1989).

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

Web Resources

proteinatlas.org